---
title: "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW"
description: "Pomerantz Law Firm is investigating claims on behalf of investors of Harrow, Inc. (NASDAQ: HROW) regarding potential securities fraud or unlawful business practices by the company and its officers. Th"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/252341747.md"
published_at: "2025-08-09T16:35:45.000Z"
---

# INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW

> Pomerantz Law Firm is investigating claims on behalf of investors of Harrow, Inc. (NASDAQ: HROW) regarding potential securities fraud or unlawful business practices by the company and its officers. This follows Harrow's disappointing Q1 2025 financial results, reporting $47.8 million in revenue, below the expected $57.0 million, and an adjusted EBITDA of -$1.9 million, missing the $11.9 million estimate. Consequently, Harrow's stock price dropped by 4.07% to $23.59 per share on May 8, 2025. Investors are encouraged to contact the firm for more information.

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Harrow and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

**\[Click here for information about joining the class action\]**

On May 8, 2025, Harrow issued a press release announcing its financial results for the first quarter of 2025. Among other items, Harrow reported revenue of $47.8 million, missing consensus estimates of $57.0 million and -$1.9 million in adjusted EBITDA, falling short of the expected $11.9 million.

On this news, Harrow’s stock price fell $1.00 per share, or 4.07%, to close at $23.59 per share on May 8, 2025.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

**CONTACT:  
**Danielle Peyton  
Pomerantz LLP  
dpeyton@pomlaw.com  
646-581-9980 ext. 7980

### Related Stocks

- [HROW.US - Harrow](https://longbridge.com/en/quote/HROW.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| LJI Wealth Management LLC Makes New Investment in Harrow, Inc. $HROW | LJI Wealth Management LLC has acquired a new position in Harrow, Inc. (NASDAQ:HROW), purchasing 30,000 shares valued at  | [Link](https://longbridge.com/en/news/272912736.md) |
| Opaleye Management Inc. Reports Disposal of Harrow Inc. Common Shares | Opaleye Management Inc. has reported the disposal of common shares of Harrow Inc. as per a recent SEC filing. The full f | [Link](https://longbridge.com/en/news/271983437.md) |
| Harrow, Inc. $HROW Shares Bought by Marshall Wace LLP | Marshall Wace LLP increased its stake in Harrow, Inc. by 31.5% in Q2, now owning 564,876 shares worth $17.25 million. Ha | [Link](https://longbridge.com/en/news/269220812.md) |
| Does Harrow’s (HROW) Debt Refinancing and Melt Pharma Deal Shift Its Long-Term Growth Trajectory? | Harrow has completed a debt refinancing and plans to acquire Melt Pharmaceuticals, enhancing its long-term growth prospe | [Link](https://longbridge.com/en/news/261504433.md) |
| FY2025 Earnings Forecast for Harrow Issued By William Blair | William Blair analysts forecast Harrow's FY2025 EPS at $0.63, with a consensus estimate of ($0.53). Q4 2025 EPS is expec | [Link](https://longbridge.com/en/news/266035887.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
